Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOGEN INC.BIIB · Entity 1675 | EVP, Human Resources | February 13, 2026 | February 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOGEN INC.
Report date February 13, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2029-02-13 | Direct | 8,025 |
Reported balance
After 2026-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-13 · Grant · Acquired 8,025 · Balance 8,025 F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 13, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 14, 2022 Filed Dec 13, 2022 01:00 UTC | BIOGEN INC. BIIB · Entity 1675 | SaleCommon Stock | 5,610 | $300.11 | $1,683,617.10 |
DisclosureSEC source: 0001127602-22-027348 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,711.0168 F1 · kind: Sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 102.4003 shares acquired under the Biogen Inc. employee stock purchase plan on 3/31/2022. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,995 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006264 · form4.xml · derivative · entry 4 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,768 Underlying: Common Stock · 1,995 shares Expires 2024-02-18 F2 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,387 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006264 · form4.xml · derivative · entry 3 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,763 Underlying: Common Stock · 1,387 shares Expires 2024-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 616 | $209.79 | $129,230.64 |
DisclosureSEC source: 0001127602-22-006264 · form4.xml · nonDerivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,218.6165 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:15 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,387 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006264 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,834.6165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,633 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004991 · form4.xml · derivative · entry 9 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,516 Underlying: Common Stock · 1,633 shares Expires 2023-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 879 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004991 · form4.xml · derivative · entry 8 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,149 Underlying: Common Stock · 879 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,505 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004991 · form4.xml · derivative · entry 7 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,505 shares Expires 2022-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 793 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004991 · form4.xml · derivative · entry 6 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,505 Underlying: Common Stock · 793 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 584 | $214.59 | $125,320.56 |
DisclosureSEC source: 0001127602-22-004991 · form4.xml · nonDerivative · entry 5 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,447.6165 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon the vesting of shares, as previously disclosed by reporting person on January 21, 2022. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 390 | $214.59 | $83,690.10 |
DisclosureSEC source: 0001127602-22-004991 · form4.xml · nonDerivative · entry 4 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,031.6165 Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 879 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004991 · form4.xml · nonDerivative · entry 3 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,421.6165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 278 | $214.59 | $59,656.02 |
DisclosureSEC source: 0001127602-22-004991 · form4.xml · nonDerivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,542.6165 Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 21:16 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 793 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004991 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,820.6165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:27 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 6,475 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-004806 · form4.xml · derivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,475 Underlying: Common Stock · 6,475 shares Expires 2025-02-10 F1 · derivative.exercise_date: The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 10, 2022. Read SEC document |
| January 19, 2022 Filed Jan 21, 2022 21:48 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 1,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-001863 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,027.6165 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2019. The shares will vest on February 12, 2022. F2 · balance_after: Includes 71.5888 shares, 14,2341 shares, 10.4331 shares and .0001 share acquired under the Biogen Inc. employee stock purchase plan on 3/31/2021, 6/30/2021, 9/30/2021 and 12/31/2021, respectively. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 21:09 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 10,150 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006976 · form4.xml · derivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,150 Underlying: Common Stock · 10,150 shares Expires 2024-02-18 F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,444 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · derivative · entry 13 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,028 Underlying: Common Stock · 1,444 shares Expires 2023-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,068 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · derivative · entry 12 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,472 Underlying: Common Stock · 1,068 shares Expires 2023-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,332 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · derivative · entry 11 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,298 Underlying: Common Stock · 1,332 shares Expires 2022-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 964 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · derivative · entry 10 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,630 Underlying: Common Stock · 964 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,005 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · derivative · entry 9 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,005 shares Expires 2021-02-12 F3 · kind: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 891 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · derivative · entry 8 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,005 Underlying: Common Stock · 891 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 474 | $278.03 | $131,786.22 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 7 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,990.3603 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 428 | $278.03 | $118,996.84 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 6 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,464.3603 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 396 | $278.03 | $110,099.88 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 5 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,892.3603 Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,068 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 4 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,288.3603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 964 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 3 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,220.3603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 891 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,256.3603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 21:56 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 884 | $278.03 | $245,778.52 |
DisclosureSEC source: 0001127602-21-006268 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,365.3603 F1 · kind: Represents shares withheld to satisfy the withholding tax liability due upon the vesting of shares, as previously disclosed by reporting person on January 29, 2021. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 21:44 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantCommon Stock | 2,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-002975 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,249.3603 F1 · shares: Represents shares earned upon satisfaction of certain performance conditions associated with performance stock units granted on February 12, 2018. The shares will vest on February 12, 2021. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:12 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 216 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022686 · form4.xml · derivative · entry 5 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 216 shares Expires 2020-08-01 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 212 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022686 · form4.xml · derivative · entry 4 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216 Underlying: Common Stock · 212 shares Expires 2020-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 95 | $274.69 | $26,095.55 |
DisclosureSEC source: 0001127602-20-022686 · form4.xml · nonDerivative · entry 3 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,691.3603 Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 212 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-022686 · form4.xml · nonDerivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,786.3603 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 20:12 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 128 | $274.69 | $35,160.32 |
DisclosureSEC source: 0001127602-20-022686 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,574.3603 F1 · balance_after: Includes 15.4542 shares, 69.717 shares and 14.1891 shares acquired under the Biogen Inc. employee stock purchase plan on 12/31/2019, 3/31/2020 and 6/30/2020, respectively. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:32 UTC | BIOGEN INC. BIIB · Entity 1675 | GrantRestricted Stock Unit · Derivative | 7,540 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005779 · form4.xml · derivative · entry 12 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,540 Underlying: Common Stock · 7,540 shares Expires 2023-02-12 F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:32 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 1,240 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005779 · form4.xml · derivative · entry 11 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,594 Underlying: Common Stock · 1,240 shares Expires 2022-02-12 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:32 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,056 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005779 · form4.xml · derivative · entry 10 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,834 Underlying: Common Stock · 1,056 shares Expires 2022-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:32 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 918 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005779 · form4.xml · derivative · entry 9 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,896 Underlying: Common Stock · 918 shares Expires 2021-02-12 F3 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:32 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 974 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005779 · form4.xml · derivative · entry 8 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,814 Underlying: Common Stock · 974 shares Expires 2021-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]). Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:32 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 1,517 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005779 · form4.xml · derivative · entry 7 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,517 shares Expires 2020-02-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The restricted stock units will vest in 2 annual installments. One-third will vest on the first anniversary of the grant date and two-thirds will vest on the second anniversary of the grant date. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:32 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 418 | $331.76 | $138,675.68 |
DisclosureSEC source: 0001127602-20-005779 · form4.xml · nonDerivative · entry 6 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,603 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:32 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,056 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005779 · form4.xml · nonDerivative · entry 5 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,021 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:32 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 286 | $331.76 | $94,883.36 |
DisclosureSEC source: 0001127602-20-005779 · form4.xml · nonDerivative · entry 4 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,965 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:32 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 974 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005779 · form4.xml · nonDerivative · entry 3 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:32 UTC | BIOGEN INC. BIIB · Entity 1675 | Tax withholdingCommon Stock | 455 | $331.76 | $150,950.80 |
DisclosureSEC source: 0001127602-20-005779 · form4.xml · nonDerivative · entry 2 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,277 Read SEC document |
| February 12, 2020 Filed Feb 14, 2020 23:32 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionCommon Stock | 1,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-005779 · form4.xml · nonDerivative · entry 1 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 20:20 UTC | BIOGEN INC. BIIB · Entity 1675 | OtherRestricted Stock Unit · Derivative | 247 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026026 · form4.xml · derivative · entry 5 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428 Underlying: Common Stock · 247 shares Expires 2020-08-01 F2 · shares: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 20:20 UTC | BIOGEN INC. BIIB · Entity 1675 | Exercise / conversionRestricted Stock Unit · Derivative | 179 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-026026 · form4.xml · derivative · entry 4 Gregory Ginger · CIK 0001545716 · EVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675 Underlying: Common Stock · 179 shares Expires 2020-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.